TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01291186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPV10O
Description: intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPV11O
Description: intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
Study: NCT00118157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO
Study: NCT04324606

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: Standard single dose of MenACWY vaccine delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY
Description: Standard single dose of MenACWY vaccine delivered intramuscularly
Study: NCT02752048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-205
Description: 2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
Study: NCT01772589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: New saw blade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reprocessed saw blade
Study: NCT03627975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: 1. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~2. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~3. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: 1. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~2. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~3. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved.
Study: NCT02004418

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-Choline
Study: NCT02350283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional treatment with Solitaire
Description: Patients will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
Study: NCT02166333

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 IU/d cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1000 IU/d cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2000 IU/d cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU/d cholecalciferol
Study: NCT00447174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic treatment for parental bereavement
Study: NCT00352742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-224 + bortezomib
Description: ATN-224 and bortezomib dose to be determined in Phase I portion of study
Study: NCT04455867

Intervention type: BEHAVIORAL
Intervention: Diabetes Exercise and Healthy Lifestyle Program
Description: The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.

Intervention type: OTHER
Intervention: Outpatient care
Description: Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
Study: NCT00349219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg taken orally daily until disease progression
Study: NCT01275521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BONT-A intra-prostatic injection
Description: • Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized medical BPH treatment
Description: Optimization of the medical therapy according to recent guidelines
Study: NCT00646607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
Description: To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
Description: standard treatment
Study: NCT04324606

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: Standard single dose of MenACWY vaccine delivered intramuscularly
Study: NCT01135901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural change programme
Description: The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
Study: NCT01139801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
Study: NCT02676518

Intervention type: OTHER
Intervention: serum
Description: Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
Study: NCT02964910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Study: NCT01129518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine
Description: In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine
Description: In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine
Description: In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.
Study: NCT00349219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
Study: NCT01129518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine schedule immunisations except monovalent MenC vaccine
Description: Routine schedule immunisations will be given according to NHS guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine schedule immunisations except monovalent MenC vaccine
Description: Routine schedule immunisations will be given according to NHS guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine schedule immunisations except monovalent MenC vaccine
Description: Routine schedule immunisations will be given according to NHS guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine schedule immunisations except monovalent MenC vaccine
Description: Routine schedule immunisations will be given according to NHS guidelines.
Study: NCT00902278

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flulaval
Description: one 0.5-mL dose via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluvirin
Description: one 0.5-mL dose via intramuscular injection
Study: NCT04324606

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: Standard single dose of MenACWY vaccine delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 full boost
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 full boost
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19
Study: NCT00902278

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: one 0.5-mL dose via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: one 0.5-mL dose via intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Afluria
Description: one 0.5-mL dose via intramuscular injection
Study: NCT04324606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 full boost
Description: A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19
Study: NCT01506986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg
Description: All three medications will be taken orally, twice daily, for seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
Description: Medication to be taken orally, twice a day, for seven days.
Study: NCT01614158

Intervention type: DEVICE
Intervention: perimetry
Description: perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) \[Schiefer 2008\] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time

Intervention type: OTHER
Intervention: D-BCVA
Description: D-BCVA using EDTRS chart

Intervention type: OTHER
Intervention: RAPD
Description: RAPD using swinging flashlight test
Study: NCT02011568

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Hypothermia

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Hypothermia
Study: NCT03362853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin 500Mg Capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500Mg Capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500Mg Capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nemonoxacin 500Mg Capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400Mg Tablet
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400Mg Tablet
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400Mg Tablet
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin 400Mg Tablet
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin 750Mg Capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750Mg Capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750Mg Capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nemonoxacin 750Mg Capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Receive a single dose in a fasting state
Study: NCT00349219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
Study: NCT03362853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Receive a single dose in a fasting state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Receive a single dose in a fasting state
Study: NCT00037934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper extremity robot
Description: Robotic upper extremity neuro-rehabilitation
Study: NCT01614158

Intervention type: DEVICE
Intervention: IOP
Description: IOP using applanation tonometer

Intervention type: DEVICE
Intervention: Spectralis OCT
Description: RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)

Intervention type: OTHER
Intervention: Fundus photography
Description: Optic disk morphology will be documented by fundus photography
Study: NCT04419701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periarticular infiltration
Description: The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: genicular nerve block
Description: The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
Study: NCT01389700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR279356
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR279356
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Study: NCT02539979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Normal Saline
Description: Normal Saline 100cc
Study: NCT03837340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMHT
Description: Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
Study: NCT00915980

Intervention type: PROCEDURE
Intervention: gastric bypass surgery and testing
Description: The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
Study: NCT02394379

Intervention type: DEVICE
Intervention: Trulign™ Toric IOL
Description: Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
Study: NCT00016406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT00003892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 5132
Description: 4mg/kg/day IV for 21 days every 4 weeks.
Study: NCT03790020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In our study this local anesthetic agent will be applied for postoperative pain relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In our study this local anesthetic agent will be applied for postoperative pain relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In our study this local anesthetic agent will be applied for postoperative pain relief
Study: NCT04127994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparing 3 versus 6 meals in type 2 diabetes patients
Description: We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparing 3 versus 6 meals in type 2 diabetes patients
Description: We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
Study: NCT04222478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific auriculotherapy
Description: 3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-specific auriculotherapy
Description: 3 sessions of auriculotherapy with semi-permanent needles on non-specific points.
Study: NCT03147040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy treatment with carboplatin and atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Chemotherapy treatment with carboplatin and atezolizumab
Study: NCT01021696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol Max. dose: 3g/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine plaster
Description: 5ųg/h, change each 7.day; max. dose: 10ųg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 25mgx1/d; max 300mg/d
Study: NCT00157573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF, sargramostim
Description: GM-CSF subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF, sargramostim
Description: GM-CSF subcutaneous injection
Study: NCT03976817

Intervention type: PROCEDURE
Intervention: aortic valve replacement
Description: After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
Study: NCT04311359

Intervention type: DRUG
Intervention: Drugs, Generic
Description: All drugs having 19 or more Brain Oedema cases reported to the FAERS database